Foreign 制药 representatives listening to a presentation at the RudaCure booth.
RudaCure set up a booth in the Rising Pavilion at 2025 Bio-韩国, recommended by KIT, and introduced the current status of 药物开发 for TRPV1-related diseases.
Chinese and American companies expressed strong interest in the overseas rights for RCI001, which is currently in 临床试验. For the 兽用 疼痛治疗药 currently under development, discussions on development stages and market were conducted through partnering meetings with a multinational 兽药 developer headquartered in the 美国.
The 非麻醉性镇痛药 development project attracted interest from investors and major domestic 制药公司, and RudaCure's booth was bustling with visitors throughout the event period.